StockData

Agios Pharmaceuticals vs Zevra Therapeutics

AGIO and ZVRA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AGIO and ZVRA compare

Agios Pharmaceuticals is the larger company, worth 3.2 times as much as Zevra Therapeutics ($1.8B against $558M).

Agios Pharmaceuticals grew revenue faster over the last twelve months (141% versus 119% for Zevra Therapeutics).

Zevra Therapeutics keeps more of each dollar of sales as profit, with a net margin of 42.8% compared with −418% at Agios Pharmaceuticals.

Zevra Therapeutics scores higher on the StockData Score (15 against 12 for Agios Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAGIOZVRA
Size and price
Market cap$1.8B$558M
Share price$29.89$9.40
Change, 1 year−31.5%5.9%
Change, 5 years−18.0%16.8%
Beta (5Y)1.541.16
Employees53961
StockData Score
Total score1215 (better)
Valuation score13 (better)
Growth score33
Performance score23 (better)
Health score66
Dividend score00
Valuation
P/E–10.1×
P/S18.1×4.1× (better)
P/B1.7× (better)2.6×
EV/EBITDA–4.0×
P/FCF–17.1×
FCF yield−20.5%5.8% (better)
Fair value$27.70$23.57
Margin of safety−7.9%60.1% (better)
Growth
Revenue growth (TTM)141% (better)119%
Revenue growth, 5Y average–51.6%
Net income growth (TTM)−163%2104% (better)
EPS growth (TTM)−163%–
Profitability
Gross margin92.0%95.5% (better)
Operating margin−467%60.5% (better)
Net margin−418%42.8% (better)
FCF margin−371%24.0% (better)
Return on equity−34.3%34.8% (better)
Return on invested capital−759%–
Financial health
Debt / equity0.000.00
Net debt / EBITDA–−2.64
Interest coverage–14.4×
Current ratio10.22 (better)5.17
Altman Z-score11.45 (better)4.35
Piotroski F-score16 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions111%78.5%
Held by insiders1.1%1.2%
Insider net buying, 12 months−$4.9M−$2.5M (better)
Short interest, % of float11.1%11.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.